TY - JOUR
T1 - The respiratory syncytial virus vaccine and monoclonal antibody landscape
T2 - the road to global access
AU - Terstappen, Jonne
AU - Hak, Sarah F.
AU - Bhan, Anant
AU - Bogaert, Debby
AU - Bont, Louis J.
AU - Buchholz, Ursula J.
AU - Clark, Andrew D.
AU - Cohen, Cheryl
AU - Dagan, Ron
AU - Feikin, Daniel R.
AU - Graham, Barney S.
AU - Gupta, Anuradha
AU - Haldar, Pradeep
AU - Jalang'o, Rose
AU - Karron, Ruth A.
AU - Kragten, Leyla
AU - Li, You
AU - Löwensteyn, Yvette N.
AU - Munywoki, Patrick K.
AU - Njogu, Rosemary
AU - Osterhaus, Ab
AU - Pollard, Andrew J.
AU - Nazario, Luiza Reali
AU - Sande, Charles
AU - Satav, Ashish R.
AU - Srikantiah, Padmini
AU - Stein, Renato T.
AU - Thacker, Naveen
AU - Thomas, Rachael
AU - Bayona, Marta Tufet
AU - Mazur, Natalie I.
N1 - Publisher Copyright:
© 2024 Elsevier Ltd
PY - 2024/1/1
Y1 - 2024/1/1
N2 - Respiratory syncytial virus (RSV) is the second most common pathogen causing infant mortality. Additionally, RSV is a major cause of morbidity and mortality in older adults (age ≥60 years) similar to influenza. A protein-based maternal vaccine and monoclonal antibody (mAb) are now market-approved to protect infants, while an mRNA and two protein-based vaccines are approved for older adults. First-year experience protecting infants with nirsevimab in high-income countries shows a major public health benefit. It is expected that the RSV vaccine landscape will continue to develop in the coming years to protect all people globally. The vaccine and mAb landscape remain active with 30 candidates in clinical development using four approaches: protein-based, live-attenuated and chimeric vector, mRNA, and mAbs. Candidates in late-phase trials aim to protect young infants using mAbs, older infants and toddlers with live-attenuated vaccines, and children and adults using protein-based and mRNA vaccines. This Review provides an overview of RSV vaccines highlighting different target populations, antigens, and trial results. As RSV vaccines have not yet reached low-income and middle-income countries, we outline urgent next steps to minimise the vaccine delay.
AB - Respiratory syncytial virus (RSV) is the second most common pathogen causing infant mortality. Additionally, RSV is a major cause of morbidity and mortality in older adults (age ≥60 years) similar to influenza. A protein-based maternal vaccine and monoclonal antibody (mAb) are now market-approved to protect infants, while an mRNA and two protein-based vaccines are approved for older adults. First-year experience protecting infants with nirsevimab in high-income countries shows a major public health benefit. It is expected that the RSV vaccine landscape will continue to develop in the coming years to protect all people globally. The vaccine and mAb landscape remain active with 30 candidates in clinical development using four approaches: protein-based, live-attenuated and chimeric vector, mRNA, and mAbs. Candidates in late-phase trials aim to protect young infants using mAbs, older infants and toddlers with live-attenuated vaccines, and children and adults using protein-based and mRNA vaccines. This Review provides an overview of RSV vaccines highlighting different target populations, antigens, and trial results. As RSV vaccines have not yet reached low-income and middle-income countries, we outline urgent next steps to minimise the vaccine delay.
UR - http://www.scopus.com/inward/record.url?scp=85204808726&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(24)00455-9
DO - 10.1016/S1473-3099(24)00455-9
M3 - Review article
C2 - 39326422
AN - SCOPUS:85204808726
SN - 1473-3099
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
ER -